Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure

被引:33
|
作者
Herweg, Bengt [1 ]
Ilercil, Arzu
Cutro, Ray
Dewhurst, Robert
Krishnan, Sendhil
Weston, Mark
Barold, S. Serge
机构
[1] Tampa Gen Hosp, Tampa, FL 33606 USA
[2] Univ S Florida, Coll Med, Tampa, FL USA
[3] Lifelink Hlth Care, Tampa, FL USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2007年 / 100卷 / 01期
关键词
D O I
10.1016/j.amjcard.2007.02.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although cardiac resynchronization therapy (CRT) is beneficial in patients with drug-refractory New York Heart Association (NYHA) class III/IV heart failure (HF) and left ventricular (LV) dyssynchrony, CRT efficacy is not well established in patients with more advanced HF on inotropic support. Ten patients (age 55 13 years) with inotrope-dependent class IV HF (nonischemic [n = 61 and ischemic [n = 4]) received a CRT implantable cardioverter-defibrillator device. QRS duration was 153 25 ms (left branch bundle block [n = 7], intraventricular conduction delay [n = 21, and QRS <120 ms [n = 1]). The indication for CRT was based on either electrocardiographic criteria (n = 9) or echocardiographic evidence of LV dyssynchrony (n = 1). Intravenous inotropic therapy consisted of dobutamine (n 6; 4.3 +/- 1.9 mu g/kg/min) or milrinone (n = 4; 0.54 +/- 0.19 mu g/kg/min) as inpatient (n = 3) or outpatient (n = 7) therapy for 146 +/- 258 days before CRT. One patient required ventilatory support before and during device implantation. All patients were alive at follow-up 1,088 284 days after CRT. Three patients underwent successful orthotopic cardiac transplantation after 56, 257, and 910 days of CRT. HF improved in 9 patients to NYHA classes II (n = 5) and III (n = 4). Intravenous inotropic therapy was discontinued in 9 of 10 patients after 15 +/- 14 days of CRT. LV volumes decreased (end-diastolic from 226 +/- 78 to 212 +/- 83 ml; p = 0.08; end-systolic from 174 +/- 65 to 150 78 ml; p <0.01). LV ejection fraction increased (23.5 +/- 4.3% to 32.0 +/- 9.1%; p <0.05). No implantable cardioverter-defibrillator shocks were recorded, and antitachycardia therapy for ventricular tachyarrhythmias was delivered in 1 patient. In conclusion, patients with end-stage inotrope-dependent NYHA class IV HF and LV dyssynchrony may respond favorably to CRT with long-term clinical benefit and improved LV function. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:90 / 93
页数:4
相关论文
共 50 条
  • [21] Tolerability Of Guideline-directed Medical Therapy In Inotrope-dependent, Stage D Heart Failure
    Faulkenberg, Kathleen D.
    Stoner, Benjamin
    Clark, Jessica L.
    Cao, Xiangkun
    Ford, Stacy L.
    Lewis, Krista J.
    Kolodziej, Andrew
    [J]. JOURNAL OF CARDIAC FAILURE, 2023, 29 (04) : 670 - 670
  • [22] Usefulness of QRS duration to predict response to cardiac resynchronization therapy in patients with end-stage heart failure
    Mollema, Sjoerd A.
    Bleeker, Gabe B.
    van der Wall, Ernst E.
    Schalij, Martin J.
    Bax, Jeroen J.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (11): : 1665 - 1670
  • [23] Cardiac resynchronization therapy (CRT) - A new option in the treatment of end-stage heart failure
    Sack, S
    Heinzel, F
    Dagres, N
    Wieneke, H
    Erbel, R
    [J]. HERZ, 2001, 26 (01) : 84 - 88
  • [24] Functional Class IV Heart Failure Patients Treated with Cardiac Resynchronization Therapy
    Castel, M. A.
    Mont, L.
    Perez-Villa, F.
    Tolosana, J.
    Sitges, M.
    Roig, R.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (02): : S101 - S101
  • [25] Cardiac resynchronization therapy in NYHA class IV heart failure
    Khoo M.
    Kelly P.A.
    Lindenfeld J.A.
    [J]. Current Cardiology Reports, 2009, 11 (3) : 175 - 183
  • [26] Cardiac resynchronization therapy in end stage heart failure patients listed for cardiac transplant
    Bedi, M. S.
    Gujral, V.
    Kormos, R.
    Murali, S.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (02): : S130 - S131
  • [27] Cardiac resynchronization therapy for patients with end stage heart failure listed for cardiac transplantation
    Bedi, MS
    Gujral, V
    Saba, S
    Ngwu, O
    Mathier, M
    McNamara, D
    Cadaret, L
    Kormos, R
    Murali, S
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 18A - 19A
  • [28] QRS duration and shortening to predict clinical response to cardiac resynchronization therapy in patients with end-stage heart failure
    Molhoek, SG
    Bax, JJ
    Boersma, E
    Van Erven, L
    Bootsma, M
    Steendijk, P
    Van Der Wall, EE
    Schalij, MJ
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2004, 27 (03): : 308 - 313
  • [29] Long-term follow-up of cardiac resynchronization therapy in patients with end-stage heart failure
    Molhoek, SG
    Bax, JJ
    Bleeker, GB
    Holman, ER
    Van Erven, L
    Bootsma, M
    Boersma, E
    Steendijk, P
    Van der Wall, EE
    Schalij, MJ
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2005, 16 (07) : 701 - 707
  • [30] Effect of right ventricular lead location on response to cardiac resynchronization therapy in patients with end-stage heart failure
    Haghjoo, Majid
    Bonakdar, Hamid Reza
    Jorat, Mohammad Vahid
    Fazelifar, Amir Farjam
    Alizadeh, Abolfath
    Ojaghi-Haghjghi, Zahra
    Esmaielzadeh, Maryam
    Sadr-Ameli, Mohammad Ali
    [J]. EUROPACE, 2009, 11 (03): : 356 - 363